Future Appears Grim For Pfizer's Tanezumab With Ostearthritis Trial Stopped
This article was originally published in The Pink Sheet Daily
Executive Summary
Because tanezumab is the anti-NGF farthest along in development, adverse event reports could spell trouble for the entire planned class of analgesics.
You may also be interested in...
Pfizer/Lilly Had Big Ambitions For Tanezumab; Are They Finally Dashed?
Given serious safety questions with tanezumab, the US filing seemed like throwing a Hail Mary; two FDA advisory panels overwhelmingly rejected the proposed risk management plan.
Lilly Shows Off R&D Progress With A Pain Franchise Built On New Mechanisms
With galcanezumab for cluster headaches and migraine and tanezumab for osteoarthritis, lower back pain and cancer pain, Lilly soon could have an up-and-running pain franchise bolstering its long-term, internal R&D strategy.
Pfizer/Lilly And J&J Are Readying NGF Inhibitors For Phase III
Pfizer and Lilly plan to resume Phase III testing of their nerve growth factor inhibitor after FDA lifted a partial hold on tanezumab. But J&J is also poised to run new Phase III studies with fulranumab.